Acorda Therapeutics (ACOR) Tops Q4 EPS by 14c
Tweet Send to a Friend
Acorda Therapeutics (NASDAQ: ACOR) reported Q4 EPS of $0.32, $0.14 better than the analyst estimate of $0.18. Revenue for the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE